Skip to main content
Clinical Trials/NCT04132804
NCT04132804
Completed
Not Applicable

Pilot Study Investigating the Effect of Tai Chi as Treatment for IBS-C

Massachusetts General Hospital1 site in 1 country31 target enrollmentJuly 21, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Irritable Bowel Syndrome With Constipation
Sponsor
Massachusetts General Hospital
Enrollment
31
Locations
1
Primary Endpoint
IBS Symptom Severity Score at 12 Weeks
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The purpose of the study is to evaluate the efficacy of Tai Chi practice in reducing symptoms of Irritable Bowel Syndrome with Constipation (IBS-C).

Detailed Description

This is a single-center pilot study investigating the efficacy of Tai Chi practice in reducing symptoms of IBS. The investigators hope that subjects practicing Tai Chi will have reduced symptoms of IBS-C as measured through overall global symptom relief as well as the IBS-SSS, IBS-QOL, VSI, HADS, Visual Analogue Pain Scale, and changes in bloating, abdominal pain, abdominal distention, and constipation severity. The study will also use daily entries made through the GeoPain app to record trends in pain intensity.

Registry
clinicaltrials.gov
Start Date
July 21, 2020
End Date
July 14, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Kyle Staller, MD, MPH

Assistant Professor in Medicine

Massachusetts General Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

IBS Symptom Severity Score at 12 Weeks

Time Frame: At final study visit, 12 weeks.

Questionnaire involves yes/no questions, entering numbers, rating scales from 0 to 100, and marking locations of pain. No subscales. Total score is derived by multiplying the number of days of pain (0 to 10) by 10 and summing it with the value from each of 4 scales (0 to 100). Higher total score represents greater symptom severity (min score= 0, max score= 500).

Secondary Outcomes

  • Likelihood of Continuing Treatment(Recorded at final study visit (following 8 weeks of treatment))
  • Treatment Satisfaction(Recorded at final study visit (following 8 weeks of treatment))
  • IBS Quality of Life (IBS-QOL) at 12 Weeks(At final study visit, 12 weeks)
  • Daily Bowel Movement Frequency at 12 Weeks(At final study visit, 12 weeks.)
  • Bloating Scale Score at 12 Weeks(At final study visit, 12 weeks)
  • Abdominal Discomfort Scale Score at 12 Weeks(At final study visit, 12 weeks.)
  • Constipation Severity Scale Score at 12 Weeks(At final study visit, 12 weeks.)
  • Hospital Anxiety and Depression Scale (HADS) Score at 12 Weeks(At final study visit, 12 weeks.)
  • Visceral Sensitivity Index (VSI) Score at 12 Weeks(At final study visit, 12 weeks)
  • Stool Microbiome(Change from baseline to final visit. Through study completion, up to 18 weeks)
  • Global Assessment of Relief at 12 Weeks(At final study visit, 12 weeks)

Study Sites (1)

Loading locations...

Similar Trials